BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 16549375)

  • 1. Variability in responsiveness to clopidogrel in patients with intermittent claudication.
    Cassar K; Bachoo P; Ford I; Greaves M; Brittenden J
    Eur J Vasc Endovasc Surg; 2006 Jul; 32(1):71-5. PubMed ID: 16549375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized clinical trial of the antiplatelet effects of aspirin-clopidogrel combination versus aspirin alone after lower limb angioplasty.
    Cassar K; Ford I; Greaves M; Bachoo P; Brittenden J
    Br J Surg; 2005 Feb; 92(2):159-65. PubMed ID: 15609386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
    Serebruany VL; Malinin AI; Pokov AN; Hanley DF
    Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiplatelet effect of clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions--limited inhibition of the P2Y12 receptor.
    Lepäntalo A; Virtanen KS; Reséndiz JC; Mikkelsson J; Viiri LE; Karhunen PJ; Lassila R
    Thromb Res; 2009 Jun; 124(2):193-8. PubMed ID: 19232433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The platelet inhibiting effect of a clopidogrel bolus dose in patients on long-term acetylsalicylic acid treatment.
    Alström U; Tydén H; Oldgren J; Siegbahn A; Ståhle E
    Thromb Res; 2007; 120(3):353-9. PubMed ID: 17137616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
    Motovska Z; Kala P
    Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination antiplatelet therapy with aspirin and clopidogrel: the role of antecedent and concomitant doses of aspirin. An analysis of 711 patients.
    Serebruany VL; Malinin AI; Atar D
    Cardiology; 2007; 107(4):307-12. PubMed ID: 17264511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clopidogrel has no effect on D-dimer and thrombin-antithrombin III levels in patients with peripheral arterial disease undergoing peripheral percutaneous transluminal angioplasty.
    Cassar K; Bachoo P; Ford I; Greaves M; Brittenden J
    J Vasc Surg; 2005 Aug; 42(2):252-8. PubMed ID: 16102623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rebound platelet activation after termination of prasugrel and aspirin therapy due to confirmed non-compliance in patient enrolled in the JUMBO Trial.
    Serebruany VL; Midei MG; Meilman H; Malinin AI; Lowry DR
    Int J Clin Pract; 2006 Jul; 60(7):863-6. PubMed ID: 16846403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized comparison of the effects of ASA plus clopidogrel versus ASA alone on early platelet activation in acute coronary syndromes with elevated high-sensitivity C-reactive protein and soluble CD40 ligand levels.
    Vavuranakis M; Latsios G; Aggelis D; Bosinakou I; Karambelas I; Tousoulis D; Toutouzas K; Stefanadis C
    Clin Ther; 2006 Jun; 28(6):860-71. PubMed ID: 16860169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual antiplatelet drug resistance in patients with acute coronary syndrome.
    Guha S; Sardar P; Guha P; Roy S; Mookerjee S; Chakrabarti P; Deb PK; Chaudhuri U; Deb S; Karmakar R; Dasgupta AK; Lahiri P
    Indian Heart J; 2009; 61(1):68-73. PubMed ID: 19729693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variability in platelet responsiveness to clopidogrel among 544 individuals.
    Serebruany VL; Steinhubl SR; Berger PB; Malinin AI; Bhatt DL; Topol EJ
    J Am Coll Cardiol; 2005 Jan; 45(2):246-51. PubMed ID: 15653023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consistent platelet inhibition during long-term maintenance-dose clopidogrel therapy among 359 compliant outpatients with documented vascular disease.
    Serebruany VL; Malinin AI; Atar D; Hanley DF
    Am Heart J; 2007 Mar; 153(3):371-7. PubMed ID: 17307414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.
    Toth PP
    Postgrad Med; 2009 Jan; 121(1):59-72. PubMed ID: 19179814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance.
    Frelinger AL; Furman MI; Linden MD; Li Y; Fox ML; Barnard MR; Michelson AD
    Circulation; 2006 Jun; 113(25):2888-96. PubMed ID: 16785341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of increased aspirin dose versus combined aspirin plus clopidogrel therapy in patients with diabetes mellitus and coronary heart disease and impaired antiplatelet response to low-dose aspirin.
    Duzenli MA; Ozdemir K; Aygul N; Soylu A; Tokac M
    Am J Cardiol; 2008 Aug; 102(4):396-400. PubMed ID: 18678294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationships between optical aggregometry (type born) and flow cytometry in evaluating ADP-induced platelet activation.
    Sbrana S; Della Pina F; Rizza A; Buffa M; De Filippis R; Gianetti J; Clerico A
    Cytometry B Clin Cytom; 2008 Jan; 74(1):30-9. PubMed ID: 17630652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of association between the 807 C/T polymorphism of glycoprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome.
    Cuisset T; Frere C; Quilici J; Morange PE; Saut N; Romero-Barra M; Camoin L; Lambert M; Juhan-Vague I; Bonnet JL; Alessi MC
    Thromb Haemost; 2007 Feb; 97(2):212-7. PubMed ID: 17264949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo.
    Erlinge D; Varenhorst C; Braun OO; James S; Winters KJ; Jakubowski JA; Brandt JT; Sugidachi A; Siegbahn A; Wallentin L
    J Am Coll Cardiol; 2008 Dec; 52(24):1968-77. PubMed ID: 19055987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.
    Angiolillo DJ; Shoemaker SB; Desai B; Yuan H; Charlton RK; Bernardo E; Zenni MM; Guzman LA; Bass TA; Costa MA
    Circulation; 2007 Feb; 115(6):708-16. PubMed ID: 17261652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.